You asked for it, and here it is: the first double-blind, randomized, and placebo-controlled trial to be published on Truehope EMpowerplus.
New Zealand researchers published today an article in the British Journal of Psychiatry a paper that outlines their investigation into the efficacy and safety of EMPowerplus in the treatment of ADHD in adults.
The researchers assigned 80 adults with ADHD into two groups: half of them used EMPowerplus, and the other half used a placebo.
After the 8-week trial, significant differences emerged between the two groups on self- and observer-ADHD rating scales. Clinicians rated those in the EMPowerplus group has having improved more—not only in ADHD symptoms, but generally, too—than the placebo group.
In addition, it seemed those with moderate or severe depression saw a greater change in mood if they were taking EMPowerplus than if they were taking the placebo.
This is great news. Our critics have been demanding these types of trials, and they validate the more than 20 studies that have been published to date. Expect more research like this in the coming months.
Researchers are already recruiting participants for another trial, which will look at children and ADHD.